葵花葯業(002737.SZ)：上半年淨利同比降22.4%至2.37億元
格隆匯 8 月 25日丨葵花葯業(002737.SZ)公佈半年報，2020年上半年，公司實現營業收入16億元，比上年同期下降32.97%；實現利潤總額3.2億元，比上年同期下降24.28%；實現歸屬於上市公司股東的淨利潤2.37億元，比上年同期下降22.40%。
2020年上半年，一場突如其來的新冠疫情席捲全球，對各行各業造成了持續影響，大環境下，整個醫藥行業，從研發、生產、流通到採購、臨牀使用，也都已經受到一定程度的影響。除個別涉及新冠疫情病毒檢測產品、防護用具及相關抗病毒治療藥品外，醫藥消費整體有所降低。
在此情形下，公司管理層審時度勢，迎難而上，有序開展疫情下的復產、復工，積極調整營銷策略、產品佈局，應對市場競爭，在保持年初制定的戰略方針總體穩定前提下加快戰術創新，保障公司各項工作的穩步推進。
但受疫情影響，公司感冒、咳嗽、退熱、消炎類產品除受國家階段性政策管控導致零售終端銷售受限外，醫院終端的就診患者管控、分流也導致公司相關產品銷售受阻，同時，加之長週期的停工停業停課和個人防護普遍增強等因素，出現了常規性流感等疾病發病率降低、相應自我診療類藥品階段性需求下降等因素，導致經營業績有所下滑。報告期內，品牌模式逐步進行組織構架優化，提升效能；進一步提升品牌模式下事業部內部團隊學術性，對操作資源、渠道進行優化、調整；提高連鎖端合作升級、打造試點打樁的重炮旅，落地產品策略，通過機制驅動，激活組織隊伍。
普藥模式在進行大區制管理模式後，制定了一系列配套政策及管理制度，進一步穩定、優化終端及產品資源，理順渠道，堅定實施既定戰略，做實大區管理，實現向一線賦能的業務前移。
處方模式加強學術推廣力度，因市制宜，為降低疫情帶來的不利影響，靈活開展各類線上學術會議，在疫情下推進地方新冠肺炎指南的准入工作，並進一步加固商務渠道建設，推進客户分級管理，鎖定核心資源開發，深度分析產品核心領域，加大終端覆蓋。
大健康領域，公司小葵花大健康逐步打造益生菌品類，從單一的內服產品線，進一步擴充益生菌用品系列產品，掌握前沿研發動態，研發新興益生菌品種進行戰略儲備；並在醫療器械、保健食品、營養品、日用品等非藥產品線精耕細作，優化產品結構、推動品類擴容，並對渠道進一步完善，實現了線下的OTC藥店、母嬰店、第三終端實體店，線上的天貓、京東、拼多多旗艦/專營店、O2O的新零售社羣營銷、微商、MCN機構帶貨等全渠道覆蓋。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
